DATRIX JOINS THE REGIONAL ARTIBAC PROJECT TO FIGHT ANTIBIOTIC RESISTANCE WITH ARTIFICIAL INTELLIGENCE

VALUED AT APPROXIMATELY €7 MILLION AND AWARDED TO A MULTIDISCIPLINARY CONSORTIUM OF SCIENTIFIC, CLINICAL, AND TECHNOLOGICAL EXCELLENCE, THE PROJECT AIMS TO DEVELOP NEW THERAPEUTIC STRATEGIES TO COMBAT ANTIBIOTIC RESISTANCE — ONE OF THE MOST SERIOUS GLOBAL HEALTH EMERGENCIES

Milan 3rd november 2025 — Datrix, a company listed on Euronext Growth Milan leading the first international AI-powered ecosystem of vertical software companies, announces its participation in ARTIBAC (Artificial Intelligence and Biotechnology Against Multidrug-Resistant Bacteria), a project funded by Regione Lombardia under the ERDF 2021–2027 – "Collabora & Innova" program.

Valued at approximately €7 million and awarded to a multidisciplinary consortium of scientific, clinical, and technological excellence, the project aims to develop new therapeutic strategies to combat antibiotic resistance — one of the most serious global health emergencies.

According to the World Health Organization (WHO), antibiotic resistance causes more than one million deaths every year worldwide and represents an increasing threat to public health and the sustainability of healthcare systems.

A LOMBARD ALLIANCE BETWEEN RESEARCH AND TECHNOLOGY

The ARTIBAC consortium brings together some of the leading organizations in Lombardy's scientific and healthcare ecosystem, including: ASST Fatebenefratelli Sacco (lead partner), University of Pavia, Fondazione Istituto Insubrico di Ricerca per la Vita, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and Fondazione Istituto Nazionale Genetica Molecolare – INGM.

Datrix participates as the technological partner, specializing in the development of advanced algorithmic models and Artificial Intelligence systems, with the goal of enhancing predictive analytics capabilities and accelerating the discovery of new antibacterial molecules.

AI AND HEALTHTECH: A STRATEGY BRIDGING EUROPE AND LOCAL INNOVATION

Participation in ARTIBAC is part of Datrix's long-term strategy in the AI & HealthTech domain, continuing its role as coordinator in two major European projects:

BETTER, which develops a distributed health data analysis platform enabling secure and decentralized processing of clinical and genomic data without moving them from their original locations;
UNICA, which extends the European Cancer Imaging Initiative by integrating oncological screening data from across Europe to improve early diagnosis and personalized care through advanced AI models and interoperable infrastructures.

As in these initiatives, in ARTIBAC Datrix contributes not only to advancing academic research but also to the "productization of scientific knowledge" — translating complex machine learning into practical applications to optimize analysis, development, and validation processes for new treatments.

AI AND BIOTECHNOLOGY FOR FASTER, MORE EFFICIENT RESEARCH

Datrix's contribution focuses on developing predictive and generative AI models capable of identifying bacterial resistance patterns and supporting the design of new bioactive compounds. By modeling experimental and clinical data, Datrix technologies will help reduce the time and cost of experimentation, improving the ability of scientific partners to validate the most promising therapeutic candidates more quickly and sustainably.

"ARTIBAC represents a new example of collaboration between academia and applied technology - comments Michele Compare, CTO of the Datrix Group - Our role is to translate the complexity of biotechnological data into intelligent and interoperable models capable of accelerating research while ensuring data security, transparency, and traceability".

THE AI OF DOING

"Participation in ARTIBAC confirms the consistency of Datrix's path with projects like UNICA and BETTER, where Artificial Intelligence becomes both a driver of knowledge and an engine of efficiency for healthcare systems adds Fabrizio Milano d'Aragona CEO of the Datrix Group - Our mission is to build a bridge between research and the market — bringing AI from the lab to clinical practice in a responsible, scalable, and sustainable way. This is our vision of AI of Doing".

***

ABOUT DATRIX

Datrix is a Group listed on Euronext Growth Milan (ISIN code IT00054683), leading the first international ecosystem of vertical Artificial Intelligence software companies.

The Group is active with AI-Based solutions in 2 business areas: AI for Data Monetization (to maximize growth opportunities in the Martech, AdTech, and FinTech sectors by transforming data into tangible value) and AI for Industrial & Business Processes (to optimize the efficiency of industrial and business processes in key sectors such as energy, manufacturing, finance, logistics, and transportation).

The Datrix Group today includes the brands: Adapex, Aramix, ByTek, FinScience and Navla.

Datrix is also a technology partner of over 20 universities and international research centers for important Research & Development projects (funded by the European Union and Italy) based on Artificial Intelligence algorithms in the fields of LifeScience/Health, Social Well Being, and Cybersecurity.

Datrix, with headquarters in Italy, operates in Europe, the United States, and the United Arab Emirates.

More info at www.datrixgroup.com

For more information:

Investor Relations: Giuseppe Venezia, tel. +39 0276281064 - [email protected] Investor Relations Consultant: Francesca Cocco (Lerxi Consulting) - [email protected]

Euronext Growth Advisor: Alantra / Stefano Bellavita, tel. +39 0263671601 - [email protected]

Marketing & Communication: Pierluigi Vacca (CMO Datrix) – [email protected] Press Office: Dario Ferrante, mob. 3891328130 - [email protected]

AI Terminal

Datrix

4409_rns_2025-11-03_65376e52-20a4-4163-b495-5b76a5cc9023.pdf

Testo del comunicato

PRESS RELEASE